Literature DB >> 17762662

Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

Richard Müller-Brunotte1, Thomas Kahan, Begoña López, Magnus Edner, Arantxa González, Javier Díez, Karin Malmqvist.   

Abstract

OBJECTIVES: Hypertensive left ventricular hypertrophy (LVH) is associated with cardiomyocyte hypertrophy and an excess in myocardial collagen. Myocardial fibrosis may cause diastolic dysfunction and heart failure. Circulating levels of the carboxy-terminal propeptide of procollagen type I (PICP), an index of collagen type I synthesis, correlate with the extent of myocardial fibrosis. This study examines myocardial fibrosis in relation to blood pressure, left ventricular mass (LVM), and diastolic function.
METHODS: We examined PICP levels in 115 patients with hypertensive LVH, 38 with hypertension but no hypertrophy, and 38 normotensive subjects. Patients with LVH were subsequently randomly assigned to the angiotensin II type 1 receptor blocker irbesartan or the beta1 receptor blocker atenolol for 48 weeks. Diastolic function was evaluated by tissue velocity echocardiography (n=134). We measured basal septal wall velocities of early (Em) and late (Am) diastolic myocardial wall motion, Em velocity deceleration time (E-decm), and isovolumic relaxation time (IVRTm).
RESULTS: Compared with the normotensive group, PICP was elevated and left ventricular diastolic function was impaired in the hypertensive groups, with little difference between patients with and without LVH. PICP related to blood pressure, IVRTm, Em, and E/Em, but not to LVM. Irbesartan and atenolol reduced PICP similarly. Only in the irbesartan group did changes in PICP relate to changes in IVRTm, and LVM.
CONCLUSION: Myocardial fibrosis and diastolic dysfunction are present in hypertension before LVH develops. The findings with irbesartan suggest a role for angiotensin II in the control of myocardial fibrosis and diastolic function in patients with hypertension with LVH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17762662     DOI: 10.1097/HJH.0b013e3282170ada

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  24 in total

Review 1.  Pharmacotherapy of heart failure with normal ejection fraction (HFNEF)--a systematic review.

Authors:  Sujit Rajagopalan; Anjuman Arora; Nusrat Shafiq; Srinivas Reddy S; Promila Pandhi; Niti Mittal; Samir Malhotra
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

2.  Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis.

Authors:  Jianrong Wang; Wenxia Lu; Jingjing Li; Rong Zhang; Yuqing Zhou; Qin Yin; Yuanyuan Zheng; Fan Wang; Yujing Xia; Kan Chen; Sainan Li; Tong Liu; Jie Lu; Yingqun Zhou; Chuan-Yong Guo
Journal:  Exp Ther Med       Date:  2017-03-09       Impact factor: 2.447

3.  Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation.

Authors:  Silvio Antoniak; Jessica C Cardenas; Laura J Buczek; Frank C Church; Nigel Mackman; Rafal Pawlinski
Journal:  Cardiology       Date:  2016-11-24       Impact factor: 1.869

4.  Impact of the PPARGC1A Gly482Ser polymorphism on left ventricular structural and functional abnormalities in patients with hypertension.

Authors:  A Rojek; M Cielecka-Prynda; M Przewlocka-Kosmala; L Laczmanski; A Mysiak; W Kosmala
Journal:  J Hum Hypertens       Date:  2014-04-10       Impact factor: 3.012

Review 5.  Heart failure with preserved ejection fraction: emerging drug strategies.

Authors:  Fouad A Zouein; Lisandra E de Castro Brás; Danielle V da Costa; Merry L Lindsey; Mazen Kurdi; George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

6.  Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo.

Authors:  Antonella Moreo; Giuseppe Ambrosio; Benedetta De Chiara; Min Pu; Tam Tran; Francesco Mauri; Subha V Raman
Journal:  Circ Cardiovasc Imaging       Date:  2009-09-03       Impact factor: 7.792

Review 7.  Extracellular matrix fibrotic markers in heart failure.

Authors:  Faiez Zannad; Patrick Rossignol; Wafae Iraqi
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

8.  IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice.

Authors:  Qianli Yu; Randy Vazquez; Elham Vali Khojeini; Chirag Patel; Raj Venkataramani; Douglas F Larson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

Review 9.  Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice.

Authors:  Yaniel Castro-Torres; Raimundo Carmona-Puerta; Richard E Katholi
Journal:  World J Clin Cases       Date:  2015-08-16       Impact factor: 1.337

Review 10.  Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.

Authors:  Brent N Reed; Sarah E Street; Brian C Jensen
Journal:  Heart Fail Clin       Date:  2014-08-14       Impact factor: 3.179

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.